Navigation Links
Sanofi US and POZEN Sign Exclusive License Agreement for the Commercialization of PA8140/PA32540 Tablets in the U.S.
Date:9/4/2013

cal application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

POZEN Forward-Looking Statements Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to license our PA product candidates on terms and timing acceptable to us, our inability to file a new drug application with the FDA for our PA product candidates in the timeframe we anticipate, our failure to successfully commercialize our product candidates; costs and delays in the devel
'/>"/>

SOURCE Sanofi US
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteurs Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older
2. Sanofi Pasteur Announces Shipment of First Lots of 2013-2014 Seasonal Influenza Vaccine in U.S.
3. Sanofi US and Joslin Diabetes Center Announce Results from Multicultural Outreach Pilot at American Diabetes Association Scientific Sessions
4. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
6. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
7. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
8. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
9. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
10. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
11. NextBio Announces Translational Medicine Partnership with Sanofi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of ... clinical results from its Phase IIa clinical trial ... to treat type 1 diabetes. The trial was conducted ... under a U.S. Food and Drug Administration (FDA) ...
(Date:10/22/2014)... 21, 2014 Influenza will affect as many as ... the United States as high as 49,000 ... spread is from person to person in respiratory droplets of ... way of death, but kills much fewer people each year ... by human fluids including sweat, saliva, blood and other bodily ...
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
... Mich., June 17 GeneGo, Inc., a leading,provider ... announced,today that they were awarded a Phase I ... of a platform for functional data analysis in,cancer. ... Boston on the project. The system, MetaMiner (Oncology) ...
... SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... Limited to,manage and provide eligible patients worldwide with ... The program will allow patients who are unable ... are considered by their physician,to be suffering from ...
Cached Medicine Technology:GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer 2Pharmaxis Establishes Named Patient Program for Bronchitol 2
(Date:10/22/2014)... 22, 2014 Shriners Hospitals for Children® ... change the current location of Shriners Hospitals for Children ... across from the University of Kentucky Albert B. Chandler ... care center, owned and operated by Shriners Hospitals for ... of children and their families well into the future. ...
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 During the ... fresh water supply runs dangerously low, Southern Oregon’s water ... Oregon’s rivers, despite the lowest mountain snow pack on ... late summer and early autumn.* That was the observation ... the new book “Hiking Southern Oregon,” during an interview ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2
... Sept. 12 Medina General Hospital and,University Hospitals ... of,Understanding in which Medina General has indicated its ... University Hospitals, network of,community- based hospitals. The agreement ... with final regulatory and governance approvals. "We,re ...
... METAIRIE, La., Sept. 12 OrthoSynetics(TM), the largest,provider ... has hired David Ward as Western Region Sales ... to serving our existing,doctors and practices, as well ... Roussos, president and CEO of OrthoSynetics(TM). "He,is yet ...
... Sept. 12 A Sept. 12 signing of ... NASA and the,National Institutes of Health in their ... entered into an agreement that helps,American scientists use ... health and diseases. The pact signals to researchers ...
... Reaches Out to Educate Chicagoans, CHICAGO, Sept. ... empower the people of Chicago, SAVE THE PATIENT, ... show on the Chicago Access Network (CAN-TV). "Community ... PM on CAN-TV, Channel 21., Monday,s program ...
... Youre whale watching in Alaska, longing for a margarita and ... did I get here" I hate the cold. Never finished ... from the Journal of Consumer Research finds that when we ... a wider array of options will sound appealing, potentially leading ...
... Former Food and Drug Administration,commissioners David Kessler and ... new legislation that strengthens prescription drug safety and,revamps ... panelists in a,conference hosted by American University and ... report from Pfizer at:, http://media.medialink.com/WebNR.aspx?story=33842 Registered ...
Cached Medicine News:Health News:Medina General Hospital and University Hospitals Agree to Pursue Affiliation 2Health News:David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager 2Health News:NASA and NIH Partner for Health Research in Space 2Health News:Health Knowledge Empowers the Public 2Health News:Wanting a bite of everything: Hungry people crave more variety 2
... Electronic Medical Record system. It stores patient chart ... and everything you would normally put in a ... Someone has to write them, file them, find ... Paper Charts get lost. They find their way ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
... The ORK WAVEFRONT ANALYZER ... the aberrations of the entire ... ability to analyze aberrations in ... of sphere, cylinder, higher order ...
... eye drops quickly remove redness ... other pollutants and provide protection ... and the sun. This unique ... LIQUIFILM®, to soothe, cool and ...
Medicine Products: